Medicare beneficiaries who use discount cards like TrumpRx to buy prescription drugs at a lower price than their plan copay face a hidden cost: those purchases do not count toward the Part D out-of-pocket cap, which rose from $2,000 in 2025 to $2,100 in 2026. The trade-off pits immediate savings at the pharmacy counter against slower progress toward the spending threshold that triggers catastrophic coverage, a protection that caps total annual drug costs for the sickest and most expensive patients.
How Discount-Card Purchases Stall Progress Toward the $2,100 Cap
The redesigned Part D benefit, shaped by the Inflation Reduction Act, limits what beneficiaries pay out of pocket for covered drugs each year. For 2026, that ceiling is set at $2,100 in annual out-of-pocket spending, an inflation-adjusted increase from the original $2,000 threshold set for 2025. Once a beneficiary hits that mark, the plan and Medicare cover all remaining drug costs for the rest of the year. Every dollar a beneficiary pays through their Part D plan counts toward that threshold, including copays, coinsurance, and deductible payments.
Discount cards operate outside that system entirely. CMS classifies TrumpRx and similar programs as something other than creditable coverage, meaning the money spent through them does not reduce the gap between a beneficiary and catastrophic protection. A beneficiary who fills three months of a generic cholesterol drug using a discount card because it costs less than the plan copay will save real money on those fills. But those dollars vanish from the Part D accounting ledger. The beneficiary’s true out-of-pocket total, known in regulatory language as TrOOP, stays exactly where it was before those purchases.
The practical result is straightforward: someone who splits their drug purchases between discount cards and their Part D plan will reach the $2,100 threshold later than someone who routes every prescription through the plan. For beneficiaries taking only inexpensive generics, the delay may never matter because they would not approach the cap regardless. For anyone also filling a high-cost specialty drug, the math changes sharply. Every discount-card purchase on a cheap maintenance medication delays the moment when catastrophic coverage kicks in and eliminates cost sharing on the expensive drug. That tension is emerging just as more beneficiaries are learning about the new cap through Medicare’s own explanations of how to manage drug expenses.
What CMS Rules Say About Cash Payments and TrOOP
Federal regulations spell out what qualifies as an incurred cost under Part D. The definitions in 42 CFR 423.100 establish the foundation for TrOOP, and a related provision in 42 CFR 423.308 addresses a narrow exception: if a beneficiary obtains a covered Part D drug at a lower cost than available under the plan, that spending can be treated as paid under the plan, but only if the beneficiary submits documentation consistent with the plan’s processes and the costs meet the regulatory definition of incurred costs. No public data shows how often beneficiaries successfully navigate that paperwork, and CMS has not published guidance simplifying the process for people who use discount cards at retail pharmacies.
A separate IRA-driven change adds another layer. Beginning in 2025, payments and discounts under the new Manufacturer Discount Program are excluded from TrOOP, according to a CMS fact sheet on the Part D redesign. That means a growing share of the total dollars flowing through a beneficiary’s prescriptions-manufacturer discounts, plan payments, and third-party assistance-will not move them any closer to the $2,100 cap. The rules preserve the basic structure of TrOOP as a measure of what patients themselves pay, but they also make the path to catastrophic coverage more opaque for anyone juggling coupons, discount cards, and assistance programs.
Weighing Immediate Savings Against Long-Term Protection
For individual beneficiaries, the policy details translate into a series of practical choices. Someone with modest drug needs who relies on a handful of low-cost generics may never come close to the out-of-pocket ceiling. In that situation, using a discount card whenever it beats the plan copay is unlikely to create a downside, because catastrophic coverage would not have been triggered anyway. The discount card simply lowers the total amount the person spends during the year.
The calculus changes for people with at least one expensive medication-such as a cancer drug, multiple sclerosis therapy, or advanced diabetes treatment-stacked on top of cheaper maintenance drugs. Those patients are the most likely to hit the cap and the most likely to benefit from reaching it earlier in the year. For them, routing every covered prescription through the Part D plan, even when a discount card looks cheaper in the moment, can accelerate progress toward the $2,100 limit and reduce overall annual spending once catastrophic coverage takes over.
Experts say the current rules effectively ask beneficiaries to predict their total drug spending for the year and to understand a complex set of definitions that even seasoned policy analysts debate. The result is a confusing landscape in which the same discount card that offers immediate relief at the pharmacy counter can quietly extend the period during which a patient pays full cost sharing on a high-price drug. Until CMS or Congress revisits how TrOOP is calculated in an era of proliferating discounts, beneficiaries and their clinicians will be left to navigate that trade-off one prescription at a time.
Free for readers: The free Retirement Shield newsletter sends plain-English help keeping more of your money in retirement — the scams to dodge, the benefits you’re owed, and what’s changing with Social Security and Medicare, a couple times a week. Get the free newsletter.
